Precision Therapeutics (NASDAQ:AIPT) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.
Valuation and Earnings
This table compares Precision Therapeutics and Smith & Nephew’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precision Therapeutics||$650,000.00||16.26||-$7.74 million||N/A||N/A|
|Smith & Nephew||$4.77 billion||3.48||$767.00 million||$1.90||19.96|
Smith & Nephew has higher revenue and earnings than Precision Therapeutics.
This table compares Precision Therapeutics and Smith & Nephew’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Smith & Nephew||N/A||N/A||N/A|
This is a breakdown of recent ratings and price targets for Precision Therapeutics and Smith & Nephew, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Smith & Nephew||0||4||2||0||2.33|
Smith & Nephew has a consensus target price of $42.00, indicating a potential upside of 10.73%. Given Smith & Nephew’s higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Precision Therapeutics.
Volatility and Risk
Precision Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
Insider and Institutional Ownership
2.3% of Precision Therapeutics shares are held by institutional investors. Comparatively, 9.0% of Smith & Nephew shares are held by institutional investors. 21.2% of Precision Therapeutics shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Smith & Nephew pays an annual dividend of $0.54 per share and has a dividend yield of 1.4%. Precision Therapeutics does not pay a dividend. Smith & Nephew pays out 28.4% of its earnings in the form of a dividend.
Smith & Nephew beats Precision Therapeutics on 9 of the 13 factors compared between the two stocks.
Precision Therapeutics Company Profile
Precision Therapeutics Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Skyline Medical Inc. and changed its name to Precision Therapeutics Inc. in February 2018. Precision Therapeutics Inc. was founded in 2002 and is based in Eagan, Minnesota.
Smith & Nephew Company Profile
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.